# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Edward Tenthoff reiterates Tempest Therapeutics (NASDAQ:TPST) with a Overweight and maintains $8 price...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows...
21 months median OS in amezalpat arm vs. 15 in control arm50% (20/40) of patients on amezalpat arm remain in survival follow up...